Before a cell dies, or an organ fails, its metabolism changes. Energy production shifts, protective molecules are used up and stress pathways switch on. Metabolomics, the broad measurement of small molecules in a biological sample, can detect these changes early.
In my master's thesis at the University of Basel, I used flow-injection mass spectrometry (FIA-MS) metabolomics to study how pharmacological agents change the metabolism of activated macrophages. This article explains why metabolomics is a powerful tool for safety assessment and what it takes to use it well.
Why metabolism is a sensitive readout
Traditional toxicity endpoints, such as cell viability or organ histopathology, often detect damage after it has happened. Metabolic changes frequently appear earlier and at lower doses (Robertson, 2005).
Metabolites are also close to the actual function of a cell. Changes in genes or proteins show what a cell could do; metabolites show what it is doing now (Johnson et al., 2016).
What metabolomics can reveal about toxicity
Well-studied examples show the kind of information metabolomics provides:
- Oxidative stress and reactive metabolites: depletion of glutathione, the cell's main antioxidant, is a classic early sign of injury, for example after paracetamol overdose (Mitchell et al., 1973).
- Mitochondrial toxicity: shifts in lactate, TCA cycle intermediates and acylcarnitines can indicate impaired energy production (Robertson, 2005).
- Cholestatic liver injury: changes in bile acid profiles can signal disturbed bile flow.
- Inflammation: activated immune cells reprogram their metabolism, so metabolic profiles can reveal immune activation (O'Neill et al., 2016).
The last point was the focus of my thesis. After LPS stimulation, macrophages shift their metabolism in characteristic ways. I studied how pharmacological agents alter that shift, alongside ELISA-based cytokine measurements.
FIA-MS: speed with trade-offs
Most metabolomics methods separate molecules by liquid chromatography before mass spectrometry. Flow-injection analysis skips that step and injects the sample directly into a high-resolution mass spectrometer (Fuhrer et al., 2011).
The advantage is speed. Each sample takes only a short time, so hundreds or thousands of samples can be profiled. That makes FIA-MS well suited to screening many compounds, doses or time points.
The trade-offs are important to understand:
- Isomers cannot be separated: molecules with the same mass appear as one signal.
- Ion suppression: abundant compounds can reduce the signal of others.
- Annotation is mass-based: identities are assigned by accurate mass, so key findings may need confirmation with a targeted method (Fuhrer et al., 2011).
Good practice makes the data trustworthy
Metabolomics generates large datasets, and small errors in design can create false findings. Reliable results depend on disciplined practice:
- Randomised sample order, so instrument drift does not line up with treatment groups.
- Quality control samples, such as pooled samples run at regular intervals, to monitor stability (Broadhurst et al., 2018).
- Blanks and controls, to separate real signals from background and contamination.
- Appropriate normalisation, for example to cell number or total signal.
- Statistics that account for many comparisons, such as false discovery rate correction (Benjamini & Hochberg, 1995).
- Traceable documentation, linking every result back to raw data and processing steps.
In my thesis, producing structured documentation and data analysis outputs consistent with regulatory research standards was a deliberate part of the work. In a regulated environment, a finding is only as credible as the record behind it.
Where metabolomics fits in a safety programme
Metabolomics does not replace standard toxicology studies. Its value lies in three areas:
Early screening. Comparing metabolic profiles of candidates can flag compounds with a toxic signature before costly studies begin.
Mechanism. When toxicity appears in animals or patients, metabolic data can help explain which pathway is affected and whether it is relevant to humans.
Biomarkers. Metabolites that change early and reliably can become translational biomarkers, monitored in both animals and humans (Johnson et al., 2016).
The link to drug safety and pharmacovigilance
Understanding mechanisms strengthens safety decisions at every stage. When a post-marketing signal suggests liver injury or an immune-mediated reaction, mechanistic data from earlier development can make the signal more or less plausible.
That is why I see my laboratory work and my pharmacovigilance interests as one continuous line: both aim to understand and anticipate harm before it reaches patients.
Why this matters to employers
Mass spectrometry-based methods are increasingly central in drug discovery and safety, from metabolomics to proteomics. Teams need people who can design experiments carefully, interpret complex data critically and communicate results clearly to toxicologists, clinicians and regulators.
My thesis gave me hands-on experience with exactly this kind of data, and my pharmacy background keeps the patient perspective in view.
Key takeaways
- Metabolic changes often appear before classical signs of toxicity.
- FIA-MS offers high throughput but needs careful design and confirmation of key findings.
- Metabolomics adds most value in early screening, mechanistic studies and biomarker discovery.
References
Benjamini, Y., & Hochberg, Y. (1995). Controlling the false discovery rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society: Series B (Methodological), 57(1), 289–300. https://doi.org/10.1111/j.2517-6161.1995.tb02031.x
Broadhurst, D., Goodacre, R., Reinke, S. N., Kuligowski, J., Wilson, I. D., Lewis, M. R., & Dunn, W. B. (2018). Guidelines and considerations for the use of system suitability and quality control samples in mass spectrometry assays applied in untargeted clinical metabolomic studies. Metabolomics, 14(6), Article 72. https://doi.org/10.1007/s11306-018-1367-3
Fuhrer, T., Heer, D., Begemann, B., & Zamboni, N. (2011). High-throughput, accurate mass metabolome profiling of cellular extracts by flow injection–time-of-flight mass spectrometry. Analytical Chemistry, 83(18), 7074–7080. https://doi.org/10.1021/ac201267k
Johnson, C. H., Ivanisevic, J., & Siuzdak, G. (2016). Metabolomics: Beyond biomarkers and towards mechanisms. Nature Reviews Molecular Cell Biology, 17(7), 451–459. https://doi.org/10.1038/nrm.2016.25
Mitchell, J. R., Jollow, D. J., Potter, W. Z., Gillette, J. R., & Brodie, B. B. (1973). Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. Journal of Pharmacology and Experimental Therapeutics, 187(1), 211–217.
O'Neill, L. A. J., Kishton, R. J., & Rathmell, J. (2016). A guide to immunometabolism for immunologists. Nature Reviews Immunology, 16(9), 553–565. https://doi.org/10.1038/nri.2016.70
Robertson, D. G. (2005). Metabonomics in toxicology: A review. Toxicological Sciences, 85(2), 809–822. https://doi.org/10.1093/toxsci/kfi102
Member discussion